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Abstract
Objective: To evaluate contrast media (CM) volume (CMV) saved using the DyeVert™ Plus
Contrast Reduction System (DyeVert Plus System, Osprey Medical) in patients undergoing diag-
nostic coronary angiogram (CAG) and/or percutaneous coronary interventional (PCI) procedures
performed with manual injections.
Background: Current guidelines advocate for monitoring and minimization of the total volume
of CM in chronic kidney disease (CKD) patients undergoing invasive cardiac procedures. The
DyeVert Plus System is an FDA cleared device designed to reduce CMV delivered during angi-
ography and permit real-time CMV monitoring.
Methods: We performed a multicenter, single-arm, observational study. Eligible subjects were ≥
18 years old with baseline estimated glomerular filtration rate (eGFR) 20–60 mL/min/1.73 m2.
The primary endpoint was % CMV saved over the total procedure. A secondary objective was
to evaluate adverse events (AEs) related to DyeVert Plus System or to CM use.
Results: A total of 114 subjects were enrolled at eight centers. Mean age was 72  9 years, 72%
were male, and mean body mass index was 29  5. Baseline eGFR was 43  11 mL/min/1.73
m2. CAG-only was performed in 65% of cases. One hundred and five subjects were evaluable for
the primary endpoint. Mean CMV attempted was 112  85 mL (range 22–681) and mean CMV
delivered was 67  51 mL (range 12–403), resulting in an overall CMV savings of 40.1  8.8%
(95% CI 38.4, 41.8; P < 0.0001) per procedure. Image quality was maintained in all but one case
where the system was turned off for one injection. No DyeVert Plus System-related AEs were
reported. Acute kidney injury (AKI; defined as serum creatinine rise of >0.3 mg/dL from baseline)
was reported in 11 cases with seven occurring in subjects with baseline eGFR < 30 and three
AKI events were attributed to CM. AKI rates increased as CMV/eGFR ratios increased.
Conclusions: These data suggest DyeVert Plus System use in CKD patients undergoing CAG
and/or PCI results in clinically meaningful CMV savings while maintaining image quality.
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1 | INTRODUCTION
Contrast-induced acute kidney injury (CI-AKI) is a common complica-
tion observed in patients undergoing invasive cardiac procedures and
is associated with increased morbidity, mortality, and health care
costs.1–5 Current professional society recommendations support iden-
tification of at risk patients, appropriate periprocedural hydration, and
minimization of contrast volume in at-risk patients as strategies to
prevent CI-AKI.6,7
There appears to be a non-linear increase in risk of AKI with
increasing doses of contrast media (CM) volume (CMV), and both
in vivo data and clinical studies have demonstrated an association
between high contrast volume and the risk of AKI.8,9 While different
authors have evaluated several contrast thresholds to guide safe con-
trast dosing, collaborative efforts to reduce the proportion of patients
exceeding threshold targets have been associated with a reduction in
the incidence of AKI.10–15
The DyeVert™ Contrast Reduction System (DyeVert System,
Osprey Medical) was cleared by the Food and Drug Administration
(FDA) for the purpose of reducing CMV delivered to patients during
angiography procedures. Early experience with this device from
European centers has demonstrated clinically and statistically mean-
ingful reductions in CM delivered to the patient.16–18 We report the
results of a single-arm, observational study evaluating the safety and
efficacy of the latest version of the product, DyeVert Plus System,
which includes continuous CM threshold monitoring, across multiple
participating sites.
2 | METHODS
2.1 | Study design and population
This was a prospective, multicenter, single-arm, observational study
designed to evaluate CMV saved using the DyeVert Plus System in a
cohort of subjects undergoing diagnostic coronary angiography (CAG)
and/or percutaneous coronary interventional (PCI) procedures per-
formed with manual injections. The study was performed at eight cen-
ters by 17 interventional cardiologists.
Local institutional review boards approved this study and all sub-
jects provided written informed consent. Eligible subjects were
≥18 years old, scheduled to undergo CAG and/or PCI, and had a base-
line estimated glomerular filtration rate (eGFR) of ≥20 and ≤60 mL/
min/1.73 m2. Subjects were excluded from participation if they: had
acute ST-elevation myocardial infarction or known coronary artery fis-
tulas, had a body mass index (BMI) >40, were currently pregnant, were
undergoing a chronic total occlusion procedure or optical coherence
tomography analysis, were planning to undergo transcatheter aortic
valve replacement within 72 hr of the index procedure, or had a con-
dition known to require large volumes of contrast (>10 mL) for each
injection.
The specific type of CM, and the use of other renal protection
strategies such as hydration, pre and post procedural laboratory stud-
ies, and continuation or discontinuation of specific medications were
at the discretion of the study investigator and per local institutional
policies. Similarly, the use of other contrast minimization techniques
such as biplane angiography and use of adjunct imaging such as IVUS
were per operator discretion and was not specified by the study
protocol.
2.2 | Study device
The DyeVert Plus System interfaces with standard manifold systems
to provide real-time contrast monitoring and reduce the amount of
contrast used in catheterization procedures while maintaining fluoro-
scopic image quality. System components include a disposable, single-
use, sterile DyeVert Plus Disposable Kit that contains a Smart Syringe
and DyeVert Plus Module, which is connected to a standard manifold
(Figure 1) and provides fluid pathway resistance modulation via a ded-
icated diversion valve. The diversion valve self-adjusts to the manual
injection pressure to divert some of the CM into the reservoir cham-
ber within the module. This diverted volume of CM does not enter
the patient.
The second component of the system is a contrast monitoring
wireless (CMW) display, which communicates with the DyeVert Plus
disposable component to allow real-time monitoring and display of
CMVs manually injected. The treating physician specified a maxi-
mum contrast dose threshold at their discretion prior to the proce-
dure. This allowed determination of the percent of the predefined
maximum CMV delivered to the patient. CM monitoring and volume
accounting is completed via translation of Hall Effect sensors and
pressure transducer voltage readings to volume readings in millili-
ters and accounting for whether contrast accounting for each injec-
tion was performed with the contrast accounting system on or off.
At the end of the procedure, the CMW displays total procedure
contrast volume used (mL, actual CMV delivered to the patient), %
of physician-specified threshold, total procedure contrast volume
saved (mL), and % contrast saved. The amount of CMV attempted to
be delivered to the patient is the sum of the total procedure con-
trast volume used (mL) and total procedure contrast volume
saved (mL).
Image quality was monitored by each operator during the proce-
dure per standard practices. Any injection in which the DyeVert Plus
System was turned off for the purpose of improving image quality
was recorded.
2.3 | Endpoints
The primary endpoint of the study was the percentage of CMV saved
over the total procedure as reported on the DyeVert Plus display at
the end of each case.
Secondary endpoints were the evaluation of DyeVert Plus
System-related adverse events (AEs) and CM-related AEs of anaphy-
laxis and AKI through discharge. Acute kidney injury events were
defined as a >0.3 mg/dL increase in serum creatinine postprocedure
through discharge compared to the baseline value or through the date
of a secondary procedure for staged procedures. Investigators defined
the etiology of each AKI event.
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2.4 | Statistical analysis
All statistical analyses were performed using SAS software, version
9.4 (SAS Institute Inc., Cary, NC, USA). The primary endpoint analysis
was based on the population of evaluable subjects and used a one
sample t-test against a fixed null hypothesis. Successful rejection of
the null hypothesis will demonstrate that the percentage of CMV
saved is statistically greater than 30%. The expected percentage of
CMV saved was estimated to be at least 35%  16%; therefore, a
sample size of 100 evaluable subjects was estimated to be required
(80% power, one-sided 0.025 alpha). To account for attrition, 114 sub-
jects were enrolled.
Subjects were deemed unevaluable for primary endpoint analysis
if any of the following criteria were met; the DyeVert Reservoir was
inadvertently turned off due to user error for >1 injection, the Dye-
Vert Reservoir was turned off for >1 injection due to an AE not
related to the device, the display did not provide contrast accounting
details at the end of a case due to device deficiency, a contrast
accounting error due to user error occurs for >1 injection as defined
in the procedure case report form, or the treating physician deter-
mines that a Bluetooth disconnection occurred resulting in inaccurate
contrast accounting.
All available data were used for the secondary endpoints.
3 | RESULTS
A total of 114 subjects were enrolled between July through
December 2017. Patient and procedure characteristics are listed in
Table 1. Baseline eGFR was 43  11 mL/min/1.73 m2 with 18 (16%)
subjects having a baseline eGFR of 20–30 mL/min/1.73 m2. Baseline
serum creatinine was 1.6  0.5 mg/dL. Nearly all subjects had history
of hypertension (96%) and 100 (88%) subjects had three or more
comorbidities in addition to chronic kidney disease (CKD). Twenty-
five (22%) subjects had New York Heart Association functional classi-
fication of heart failure Stage III (moderate) or IV (severe). Subjects
were, on average, at a moderate risk for AKI according to the Mehran
risk score.
Most procedures were CAG only (65%) and were performed using
femoral access (63%) and 6 Fr (73%) catheters. Mean pre-defined
physician CM threshold per procedure was 122  50 mL and were
set using criteria of eGFR x < 2 not to exceed 314 in 66% of proce-
dures, eGFR x < 3.719 in 24% of procedures, and other methods in
11% (ePRISM or physician discretion). Cath lab staff reported the
DyeVert Plus System setup and priming added 3.3  2.9 min to pro-
cedure preparation.
Staged PCI was performed in 11 subjects. Post-procedure serum
creatinine measurement was obtained in 54 (47%) subjects as part of
routine clinical care. Same-day discharge occurred in 63 (55%) sub-
jects, 27 (24%) subjects were discharged the day after the procedure,
five (4%) subjects were discharged 2 days after the procedure and
19 (17%) subjects were discharged three or more days after the
procedure.
3.1 | Primary endpoint
Nine subjects were excluded from the primary endpoint analysis per
the protocol. In eight cases, the DyeVert Plus System was not used
for more than one injection during the case due to user or technical
error. In one case, the subject met study exclusion criteria for BMI but
was inadvertently enrolled in the study. Therefore, 105 subjects were
evaluable for the primary endpoint.
FIGURE 1 The DyeVert™ Plus System [Color figure can be viewed at wileyonlinelibrary.com]
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The mean predetermined CMV threshold in the primary endpoint
cohort was 119  48 mL (range 40–236 mL). The mean CMV
attempted was 112  85 mL (range 22–681 mL) and mean CMV
delivered was 67  51 mL (range 12–403 mL) resulting in an overall
CMV savings of 40.1  8.8% (95% CI 38.4, 41.8; P < 0.0001) per pro-
cedure (Figure 2). In 91 (87%) cases, the CMV delivered was less than
the predefined CM threshold.
When the primary analysis was additionally performed using all
cases (inclusive of the excluded cases), the overall CMV savings was
39.4  9.1% (95% CI 37.7, 41.1; P < 0.0001) per procedure.
Image quality was maintained in all but one CAG + PCI case, in
which the physician turned off the DyeVert Plus System for one injec-
tion for the purpose of obtaining a better image, and then resumed
using the DyeVert Plus System for the remainder of the case.
Prespecified subgroup analyses were performed to assess if con-
trast savings varied within access approach (radial vs. femoral), BMI
(<30 kg/m2 vs. ≥30 kg/m2), physician user, and procedure type
(Table 2). While a large average contrast savings was observed in all
subgroups, there were significant differences in contrast savings
(P < 0.05) for subgroups defined by BMI and procedure type, with
more savings observed for those with a lower BMI and for diagnostic
procedures. Contrast savings also varied significantly between physi-
cian users (P = 0.0029).
3.2 | Secondary endpoints
All enrolled subjects contributed to the secondary endpoint analysis.
No DyeVert Plus System-related AEs or cases of contrast-related ana-
phylaxis were reported. Acute kidney injury (>0.3 mg/dL increase in
serum creatinine postprocedure through discharge) was reported in
11 subjects for an observed AKI rate of 9.6% (11/114). The adjusted
AKI rate, including only those subjects with a post-procedure serum
TABLE 1 Patient and procedural characteristics
Patient characteristics
Age (years) 72  9
Gender
Male 82 (72)
Female 32 (28)
Race
Caucasian 86 (75)
African American 25 (22)
Asian 1 (1)
American Indian 1 (1)
Other 3 (3)
BMI 29  5
eGFR (mL/min/1.73 m2) 43  11
Serum creatinine (mg/dL) 1.6  0.5
Comorbidities
Hypertension 110 (96)
Coronary artery disease 86 (75)
Prior PCI 60 (53)
Diabetes 60 (53)
Congestive heart failure 54 (47)
Prior coronary artery bypass graft 40 (35)
Prior myocardial infarction 39 (34)
Anemia 33 (29)
Angina 30 (26)
Mehran risk scorea (using eGFR) 9.0  3.9
Procedure characteristics
Vascular access route
Femoral 72 (63)
Radial 42 (37)
Procedure type
CAG only 74 (65)
CAG + PCI 30 (26)
PCI only 10 (9)
CM type used
Visipaque 320 63 (55)
Omnipaque 350 20 (18)
Omnipaque 300 16 (14)
Isovue 8 (7)
Visipaque 270 7 (6)
Fluoroscopy time (min) 12.8  14.4
# Lesions treated
0 74 (65)
1 29 (25)
2 7 (6)
3 2 (2)
4 1 (1)
5 0 (0)
6 1 (1)
Maximum catheter size (per subject)
4F 1 (1)
5F 20 (18)
6F 79 (73)
(Continues)
TABLE 1 (Continued)
Patient characteristics
7F 9 (8)
Catheter size (total reported for all cases)
4F 1 (1)
5F 42 (22)
6F 141 (73)
7F 10 (5)
Data are n (%) or mean  SD.
a Intra-aortic balloon pump use and hypotension were not collected in this
study; risk score integers were assumed 0 for these factors.
FIGURE 2 Mean contrast media volume attempted (total procedure
contrast volume delivered + total procedure contrast volume saved)
versus delivered to the patient
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creatinine value, was 20.4% (11/54). Seven AKI events occurred in
subjects with baseline eGFR <30. Investigators attributed the AKI
events to the following causes: five (4.4%) were fluid management
related (over- or under-diuresis, diuretic use/congestive heart failure),
three (2.6%) were contrast-related, one was related to a diabetic
complication, one was due to a recent prior surgery, and in one case,
the cause was unknown.
Using an AKI definition of ≥0.5 mg/dL increase in serum creati-
nine postprocedure through discharge, six AKI events were reported
for an observed AKI rate of 5.3% (6/114) and an adjusted rate of
11.1% (6/54). Based on an imputed Mehran risk score20 (hypotension
and use of IABP were assumed to be 0 for all subjects since these var-
iables were not prospectively collected) calculated for this cohort, the
predicted risk of AKI (defined as an elevation in serum creatinine of
>0.5 mg/dL) for the overall cohort and the patients with follow up
serum creatinine data was 14%.
Use of the DyeVert Plus System was associated with a lower
observed CMV/eGFR ratios for the study cohort compared to the
attempted CMV/eGFR ratios (reflective of the amount of contrast the
subject would have been given without the use of DyeVert Plus);
therefore, a substantial proportion of subjects moved into lower
CMV/eGFR deciles (Figure 3). At lower CMV/eGFR ratios, the use of
DyeVert Plus increased the percentage of subjects with ratios ≤1 from
7% (attempted) to 33% (actual) and with ratios ≤2 from 42%
(attempted) to 75% (actual). Conversely, at higher CMV/eGFR ratios,
the use of DyeVert Plus reduced the percentage of subjects with
ratios >2 from 58% (attempted) to 25% (actual).
Observed AKI rates increased with increasing CMV/eGFR ratios
(Figure 4), with an observed AKI rate of 0% for subjects with a
CMV/eGFR of ≤1 and 22.2% for subjects with a CMV/eGFR >3
although the number of AKI events and number of subjects with a
high CMV/eGFR was limited.
4 | DISCUSSION
Our study demonstrates the feasibility of using the DyeVert Plus Sys-
tem to achieve a meaningful reduction in contrast volume delivered to
TABLE 2 Contrast volume savings, subgroup analyses
Variable Percent contrast savings P-valuea
Access location 0.1558
Femoral 39.2  8.6 (68)
Radial 41.8  9.0 (37)
BMI 0.0398
<30 41.6  8.0 (61)
≥30 38.0  9.5 (44)
Physician 0.0029
Physician user 1 32.7  7.5 (18)
Physician user 2 42.3  5.4 (16)
Physician user 3 41.5  12.3 (15)
Physician user 4 41.5  8.2 (14)
Physician user 5 35.9  5.1 (5)
Physician user 6 44.9  5.4 (5)
Physician user 7 48.6  5.0 (5)
Physician user 8 40.7  7.4 (4)
Other usersb 40.6  8.0 (23)
Procedure type 0.0057
Diagnostic only 41.9  8.4 (70)
Diagnostic + PCI 37.4  8.7 (25)
PCI only 34.1  7.8 (10)
Data are presented mean  std (n).
a P-value based on two sample t-test or ANOVA for subgroup variables with
more than two levels.
b Physicians with fewer than four cases were combined into Other Users.
FIGURE 3 Contrast media volume/baseline estimated glomerular filtration rate ratio attempted (total procedure contrast volume
delivered + total procedure contrast volume saved) versus delivered to the patient (actual) using DyeVert Plus
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patients undergoing CAG and/or PCI. This was accomplished by a
lowering of the CMV-to-eGFR ratio; and thus, a left-ward shift of the
renal function-based contrast dose curve. The overall magnitude of
the CMV saved was both clinically meaningful and statistically signifi-
cant. The device was easy to set up and use and no device related
complications were observed. In the majority of cases, the CMV deliv-
ered was less than the predefined CMV threshold. The observed AKI
rate in this study was significantly lower than predicted and adds to
the large body of data suggesting that strategies to reduce CMV can
result in improved patient outcomes.
Diagnostic CAG and PCIs are among the most common proce-
dures using intra-arterial CM and AKI remains one of the most com-
mon and expensive complications in this population. There is a large
body of data suggesting that higher renal function-adjusted CM dose
is associated with a higher risk of AKI.4,19–27 While the exact thresh-
old for defining renal safety remains debatable, it is clear that patients
who receive higher CM doses are at greater risk of AKI, compared
with those who receive lower doses. Furthermore, recent data sug-
gest that collaborative efforts to reduce CMV have been associated
with a reduction in the incidence of AKI.13–15
Current PCI performance standards support careful ascertainment
of CMV in patients undergoing PCI although this practice remains far
from universal. A recent landmark study of over 1.3 million PCIs by
Amin et al. demonstrated inconsistent and significant variation in con-
trast use among physicians and minimal reduction in CMV for patients
at higher risk for AKI.28 In a recent physician survey carried out by
SCAI, 40% of respondents reported estimating CMV without using a
measurement technique and 40% of respondents reported not using
CMV threshold limits for patients at risk of AKI.29
The average volume of CM administered to the patients in this
study (67 mL) compares favorably with the volume administered in
recent randomized controlled trials (median of 85 mL reported in the
PRESERVE trial30) or in routine clinical practice (mean of 198 mL
reported by Amin et al.28 and 168 mL reported by Gurm et al.31). Con-
current with the reduction in CMV, the use of DyeVert Plus resulted
in a shift in the actual versus attempted CMV/eGFR ratio. Since the
association between AKI and CMV/eGFR is non-linear, a left-ward
shift would be expected to significantly reduce the incidence of AKI.
Indeed, none of the patients in whom the CMV/eGFR ratio was less
than 1, developed AKI. Further studies to explore the utility of this
threshold in high risk patients are warranted.
The DyeVert Plus System probably impacts contrast dose via two
related yet equally important mechanisms. First, by minimizing wasted
reflux into the aortic root, the system directly reduces the CMV
administered to the patient. Second, by providing direct monitoring of
the total CMV delivered to the patient, the system provides direct
feedback to the operator and permits modifying the procedure to
ensure that the predetermined CM threshold is not exceeded. Finally,
the DyeVert Plus System attunes the entire catheterization laboratory
to the importance of CM thresholds and CMV minimization and
potentially helps drive renal safety in the catheterization laboratory.
4.1 | Study limitations
We used an objective performance criterion based on published litera-
ture instead of a concurrent control group. Additionally, data on CI-
AKI should be construed as hypothesis-generating as postprocedure
laboratory data were not available on all patients and CI-AKI was
based only on clinically available subject data. AKI events were not
available beyond discharge and were not centrally adjudicated. How-
ever, the system did significantly reduce administered CM dose, which
has been shown to directly correlate with CI-AKI in prior studies.
5 | CONCLUSION
These data suggest DyeVert Plus System use in CKD subjects under-
going CAG and/or PCI procedures results in statistically significant
and clinically meaningful CMV savings while maintaining image qual-
ity. CMV savings resulted in a meaningful proportion of subjects mov-
ing to lower contrast volume-to-eGFR ratios and exploratory analyses
FIGURE 4 Acute kidney injury rates by contrast media volume to baseline estimated glomerular filtration rate ratio
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showed that CI-AKI event rates were significantly lower in subjects
with lower contrast volume-to-eGFR ratios.
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